Alex Klarer has a background in Chemical Engineering focused on bioprocessing and process engineering. Over the last 7 years, he has held roles at Genentech and Hitachi where he led the translational process development for a range of cell therapies and ex-vivo gene therapies including T-cell, DC and NK cell immunotherapies, stem cell therapies, and MSC mediated immunoregulation. Alex also has experience developing novel technologies and applications to address gaps in manufacturing capabilities.
